01 February 2023 |
27 January 2023 |
Information regarding COVID-19 vaccine efficacy |
H2022018675 response (pdf, 212 KB) |
01 February 2023 |
27 January 2023 |
Information regarding emergency department waiting times |
H2022018291 response (pdf, 6.1 MB) H2022018291 - Appendix 2 (xlsx, 51 KB) |
01 February 2023 |
27 January 2023 |
Information related to Principal Advisors at Manatū Hauora |
H2023018988 response (pdf, 2.3 MB) |
01 February 2023 |
26 January 2023 |
Information regarding drinking water data |
H2022018821 response (pdf, 228 KB) H2022018821 - Appendix 1 (xlsx, 245 KB) |
01 February 2023 |
25 January 2023 |
Information regarding face masks |
H2022018342 response (pdf, 277 KB) |
01 February 2023 |
24 January 2023 |
Information regarding guidelines for COVID-19 vaccination of children |
H2022018201 response (pdf, 225 KB) |
24 January 2023 |
18 January 2023 |
Information related to the COVID-19 vaccine |
H2022018490 response (pdf, 1.7 MB) |
24 January 2023 |
18 January 2023 |
Information related to the International Health Regulations (IHR) |
H2022015383 response (pdf, 23.5 MB) |
24 January 2023 |
17 January 2023 |
Information on the COVID-19 vaccine, testing and response budget |
H2022018361 response (pdf, 220 KB) |
24 January 2023 |
16 January 2023 |
Information on Pfizer Cumulative Analysis Report of PF-07302048 |
H2022018890 response (pdf, 194 KB) |
24 January 2023 |
16 January 2023 |
Information on the classification of cannabidiol |
H2022017633 response (pdf, 178 KB) |
24 January 2023 |
16 January 2023 |
Information on the Focus Group meetings for NEAC |
H2022017383 response (pdf, 8 MB) |
24 January 2023 |
16 January 2023 |
Information regarding staffing at Manatū Hauora |
H2022017774 response (pdf, 234 KB) |
24 January 2023 |
30 November 2022 |
Information on the regulatory impact statement on regulating natural health products |
H2022016152 response (pdf, 211 KB) H2022017883 response (pdf, 2.2 MB) H2022017883 follow up response (pdf, 222 KB) |
16 January 2023 |
13 January 2023 |
Information on cannabidiol & tetrahydrocannabinol products |
H2022017793 response (pdf, 196 KB) |
16 January 2023 |
13 January 2023 |
Information on end-of-year functions at Manatū Hauora |
H2022017746 response (pdf, 255 KB) |
16 January 2023 |
12 January 2023 |
Information on social media management at Manatū Hauora |
H2022017765 response (pdf, 203 KB) |
16 January 2023 |
12 January 2023 |
Information regarding the Pfizer COVID-19 vaccine |
H2022018097 response (pdf, 177 KB) |
16 January 2023 |
12 January 2023 |
Information relating to antimicrobial resistance in fungal organisms |
H2022017744 response (pdf, 232 KB) |
16 January 2023 |
11 January 2023 |
Information on the communications team at Manatū Hauora |
H2022017745 response (pdf, 218 KB) |
16 January 2023 |
11 January 2023 |
Information regarding amendments to the Mental Health Act |
H2022017874 response (pdf, 2.4 MB) |
16 January 2023 |
11 January 2023 |
Information regarding the Pfizer COVID-19 vaccine |
H2022018695 response (pdf, 143 KB) |
16 January 2023 |
09 January 2023 |
Information regarding psychoactive substance licenses |
H2022017627 response (pdf, 177 KB) |
16 January 2023 |
23 December 2022 |
Information on working from home policy at Manatū Hauora |
H2022017741 response (pdf, 225 KB) |
16 January 2023 |
23 December 2022 |
Information regarding Manatū Hauora employee statistics |
H2022017605 response (pdf, 296 KB) |